Detalles de la búsqueda
1.
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
Oncologist
; 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38630540
2.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858721
3.
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
J Urol
; 209(4): 701-709, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36573926
4.
A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System.
J Urol
; 208(4): 804-812, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35686812
5.
Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials.
Support Care Cancer
; 27(4): 1551-1561, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30547303
6.
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer
; 124(18): 3677-3683, 2018 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30307610
7.
Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
Clin Genitourin Cancer
; 22(3): 102060, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38521648
8.
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience.
Can Urol Assoc J
; 18(3): E73-E79, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38010229
9.
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
J Thorac Oncol
; 19(6): 941-953, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38159809
10.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
Eur Urol
; 86(1): 4-9, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582713
11.
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
Eur Urol Oncol
; 7(3): 570-580, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38097481
12.
Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum.
Can Urol Assoc J
; 18(4): E127-E137, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38381937
13.
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol
; 2024 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38290965
14.
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.
Prostate Cancer Prostatic Dis
; 26(1): 74-79, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35197558
15.
Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
Cancer Rep (Hoboken)
; 6(3): e1763, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36517084
16.
Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population.
Urol Oncol
; 41(7): 328.e15-328.e23, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37202328
17.
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.
Can Urol Assoc J
; 17(5): E154-E163, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37185210
18.
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol Oncol
; 2023 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914579
19.
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.
Ther Adv Med Oncol
; 14: 17588359221108685, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35782749
20.
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.
Adv Radiat Oncol
; 7(4): 100899, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35814860